Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma ; volume:124 ; number:1 ; day:7 ; month:10 ; year:2020 ; pages:237-246 ; date:1.2021
British journal of cancer ; 124, Heft 1 (7.10.2020), 237-246, 1.2021
- Urheber
-
Lee, Chung-Han
Motzer, Robert J.
Glen, Hilary
Michaelson, M. D.
Larkin, James
Minoshima, Yukinori
Kanekiyo, Michio
Ikezawa, Hiroki
Sachdev, Pallavi
Dutcus, Corina E.
Funahashi, Yasuhiro
Voß, Martin Henner
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-020-01092-0
- URN
-
urn:nbn:de:101:1-2021020611175554089997
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Chung-Han
- Motzer, Robert J.
- Glen, Hilary
- Michaelson, M. D.
- Larkin, James
- Minoshima, Yukinori
- Kanekiyo, Michio
- Ikezawa, Hiroki
- Sachdev, Pallavi
- Dutcus, Corina E.
- Funahashi, Yasuhiro
- Voß, Martin Henner
- SpringerLink (Online service)
Ähnliche Objekte (12)
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
The Development of Lenvatinib-Induced Pancreatitis in a Patient with Metastatic Neuroendocrine Tumor: A Case Report
Sichere Anwendung von Everolimus
Reanalyzing German correlative "es"
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
The Development of Lenvatinib-Induced Pancreatitis in a Patient with Metastatic Neuroendocrine Tumor: A Case Report
Sichere Anwendung von Everolimus
Reanalyzing German correlative "es"
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
The Development of Lenvatinib-Induced Pancreatitis in a Patient with Metastatic Neuroendocrine Tumor: A Case Report
Sichere Anwendung von Everolimus